← back to search

Jeffrey R. Marks

Duke University · US
Area of research
Cancer Research · Reproductive Medicine
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Cancer Genomics and Diagnostics, Breast Cancer Treatment Studies, and Cancer Cells and Metastasis.
h-index
95
citations
46,916
works
596
NIH funding
primary concept
Medicine
email

Recent publications

Spatially Discontinuous Mutation Topographies in Ductal Carcinoma <i>In Situ</i> Reveal Noncompetitive Growth Dynamics
Cancer Research 2025cited by 0position: middledoi
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
JAMA 2024cited by 64position: middledoi
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions
The American Journal of Human Genetics 2024cited by 25position: middledoi
Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms
Cancer Epidemiology Biomarkers & Prevention 2024cited by 11position: middledoi
Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome
Breast Cancer Research 2024cited by 7position: middledoi
Archival single-cell genomics reveals persistent subclones during DCIS progression
Cell 2023cited by 54position: middledoi
Association of inflammation-related exposures and ovarian cancer survival in a multi-site cohort study of Black women
British Journal of Cancer 2023cited by 9position: middledoi
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts
Cancer Cell 2022cited by 88position: middledoi
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer
Nature Genetics 2022cited by 87position: middledoi
Abstract PO-232: Racial differences in the tumor immune landscape and survival of high-grade serous ovarian carcinoma
Cancer Epidemiology Biomarkers & Prevention 2022cited by 0position: middledoi
Abstract PR010: Characterizing N-glycan profiles of DCIS progression using tissue imaging MALDI mass spectrometry
Cancer Prevention Research 2022cited by 0position: middledoi
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer
Cell Reports 2019cited by 92position: middledoi
Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set
Breast Cancer Research and Treatment 2018cited by 195position: middledoi
LncRNA CamK-A Regulates Ca2+-Signaling-Mediated Tumor Microenvironment Remodeling
Molecular Cell 2018cited by 184position: middledoi
Expression of Long Noncoding RNA <i>YIYA</i> Promotes Glycolysis in Breast Cancer
Cancer Research 2018cited by 79position: middledoi
The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors
Nature Cell Biology 2017cited by 268position: middledoi
JAK2-binding long noncoding RNA promotes breast cancer brain metastasis
Journal of Clinical Investigation 2017cited by 230position: middledoi
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Cell 2015cited by 1,947position: middledoi
Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion
Breast Cancer Research 2015cited by 45position: middledoi
Common variants at the<i>CHEK2</i>gene locus and risk of epithelial ovarian cancer
Carcinogenesis 2015cited by 28position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David H. Hawke · The University of Texas Health Science Center at Houston3 papers (2017–2018)Robert B. West · University of Leeds3 papers (2022–2025)Liuqing Yang · The University of Texas MD Anderson Cancer Center3 papers (2017–2018)Ke Liang · Nanchang University3 papers (2017–2018)Joellen M. Schildkraut · Institute of Biomedical Sciences, Academia Sinica3 papers (2022–2024)Mien‐Chie Hung · Institute of Biomedical Science3 papers (2017–2018)Lauren C. Peres · Moffitt Cancer Center3 papers (2022–2024)Qingsong Hu · Soochow University3 papers (2017–2018)Jianwei Zhou · Jiangsu University3 papers (2017–2018)Chunlai Li · Regend Therapeutics (China)3 papers (2017–2018)Chunru Lin · The University of Texas MD Anderson Cancer Center3 papers (2017–2018)Andrew Berchuck · Duke University2 papers (2022–2024)Aifu Lin · Ministry of Education of the People's Republic of China2 papers (2017–2018)Anthony J. Alberg · University of Alabama at Birmingham2 papers (2022–2023)Leng Han · Indiana University Health2 papers (2017–2018)Guolin Ma · Texas A&M University2 papers (2017–2018) · 2 papers (2023–2024)Peter K. Park · The University of Texas at Austin2 papers (2017–2018)Yubin Zhou · UCLA Health2 papers (2017–2018)Jennifer A. Doherty · University of Utah2 papers (2022–2024)